期刊文献+

结缔组织病诊疗进展 被引量:1

下载PDF
导出
摘要 结缔组织病(Connective Tissue Disease,CTD)有广义和狭义之分,广义的结缔组织病是指体内结缔组织各种疾病的总称。狭义的结缔组织病是指由于免疫反应等引起的发生于疏松结缔组织的一类疾病。目前我们所指的结缔组织病系指狭义的结缔组织病,包括红斑狼疮(Lupus Erythematosus,LE)、皮肌炎/多肌炎(Dermatomyositis/Polymyositis,DM/PM)、硬皮病(Scleroderma)、类风湿性关节炎(Rheumatoid Arthritis,RA)、混合性结缔组织病(Mixed Connectijce Tissue Disease,MCTD)、干燥综合征(Siogren’s Syndrome,SS)及重叠综合征(Overlap Svndrome)等。
作者 李明
出处 《继续医学教育》 2007年第23期22-28,共7页 Continuing Medical Education
  • 相关文献

参考文献16

  • 1Tan EM,Cohen AS,Fries JF,et al.The 1982 revised criteria for the classification of systemic lupus erythematosus[J].Arthritis Rheum,1982,25:1271-1277.
  • 2蒋明.风湿病学[M].北京:华夏出版社,2004.886-942.
  • 3吴杰,李明.系统性红斑狼疮复发预测的初步研究[J].中华皮肤科杂志,2005,38(1):14-16. 被引量:6
  • 4胡东艳,李明.系统性红斑狼疮病情活动相关因素的研究[J].中华皮肤科杂志,2003,36(1):16-19. 被引量:13
  • 5李明.红斑狼疮的临床用药[J].世界临床药物,2003,24(8):467-471. 被引量:6
  • 6Cathcart ES,Idelson BA.Beneficial effects of methyprednisolone"pulse"therapy in diffuse proliferative lupus nephritis[J].Lancet,1976,7:163-166.
  • 7Edwards JC,Snaith ML.A double blind controlled trial of methylprednisolone infusions in systemic lupus erythematosus using individualized outcome assessment[J].Ann Rheum Dis,1987,46(10):773-776.
  • 8Austin III HA,Klippel JH,Balow JE,et al.Therapy of lupus nephritis:Controlled trial of prednisone and cytotoxic drugs[J].N Eng J Med,1986,314:614-619.
  • 9Goldman L eds.Cecil Textbook of Medicine[M].Philadelphia:Saunders,2004.1660-1670.
  • 10Rich RR.Clinical Immunology[M].London:Mosby,2001,60:1-24.

二级参考文献23

  • 1李明.结缔组织病诊疗进展[J].继续医学教育,2006,20(23):48-53. 被引量:2
  • 2邱凯锋,林茵.系统性红斑狼疮的临床用药进展[J].中国药房,2006,17(14):1108-1110. 被引量:5
  • 3张雷杰,张本法.高压氧综合治疗系统性硬皮病10例[J].中华航海医学杂志,1996,3(4):243-243. 被引量:3
  • 4Petri M, Genovese M, Engle E, et al. Definition, incidence, and clinical description of flare in systemic' lupus erythematosus. A prospective cohort study. Arthritis Rheum, 1991, 34: 937-944.
  • 5ter Borg EJ, Horst G, Hummel EJ, et ah Measurement of increases in anti-double-stranded DNA antibody levels as a prcdietor of disease exacerbation in systemic lupus erythematosus. A long-term.prospective study. Arthritis Rheum, 1990. 33: 634-643.
  • 6Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum.1982, 25: 1271-1277.
  • 7Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992, 35: 630-640.
  • 8Livneh A, Or G, Many A, et al. Anti-DNA antibodies secreted by peripheral B cells of lupus patients have hoth normal and lupusspecific features. Clin Immunol Immunopathol. 1993.68: 68-73.
  • 9Miret C, Font J, Molina R, et al. Bcl-2 oncogene (B cell lymphoma/leukemia-2) levels correlate with systemic lupus erythematosus disease activity. Anticancer Res, 1999, 19: 3073-3076.
  • 10Jodo S, Kobayashi S, Kayagaki N, el al. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases.Clin Exp Immunol, 1997, 107: 89-95.

共引文献78

同被引文献13

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部